IL17A and asthma: For example, studies (Liu et al., 2023) have confirmed that the CHM prescription YPF and its main active compound wogonin may alleviate airway inflammation in asthma by inhibiting PI3K/AKT, IL-17 and TNF-α signaling pathways.